Dual CMV and HIV CARs for Cure of HIV
Dual CMV and HIV CARs for Cure of HIV
批准号:
10001141
负责人:
OTTO O YANG
金额:
$19.5万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-03-05 至 2022-02-28
关键词:
Abnormal CellAcuteAddressAftercareAnimalsAntigensAntiviral AgentsAreaAutomobile DrivingBackBindingCD8-Positive T-LymphocytesCell surfaceCellsChronicChronic PhaseClonal ExpansionContainmentCytomegalovirusCytoplasmic ProteinCytotoxic T-LymphocytesDataDefectDetectionDropsEffector CellEngineeringEvolutionFailureFunctional disorderFutureGenerationsGenome ScanGoalsHIVHIV InfectionsHIV vaccineHIV-1Histocompatibility Antigens Class IHumanImmuneImmunityIn VitroInfectionInfection ControlInterruptionLaboratoriesLentivirus VectorMacacaMaintenanceMajor Histocompatibility ComplexMalignant NeoplasmsMediatingMemoryMutationNatural regenerationPathogenesisPathogenicityPathway interactionsPeptidesPersonsPlayPopulationProcessProteinsPublic HealthReceptor SignalingRestRoleSIVSamplingScanningStimulusT-Cell ReceptorTestingTextTherapeuticTransportationViralViremiaVirusVirus Replicationacute infectionadaptive immunityantiretroviral therapyarmcancer therapychimeric antigen receptorchimeric antigen receptor T cellschronic infectioncytotoxic CD8 T cellsexhaustiongene therapyimprovedin vivomulticatalytic endopeptidase complexpathogenpreventresponsevector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
CD8+ cytotoxic T lymphocytes (CTLs) play a key role protective role in the immunopathogenesis of HIV-1
infection, but eventually fail in most persons due to lagging behind the virus. Numerous data indicate that HIV-
1-specific CTLs mediate the suppression of HIV-1 that mediates the “asymptomatic phase” of chronic infection.
The CTL response arises by clonal expansion from the naïve cell population, and once the antigen is cleared
to low or absent levels, most of these cells die, leaving resting central memory cells with low effector function,
but which are primed for more rapid expansion upon re-challenge to effector cells. This process results in the
lag of CTLs behind HIV-1, and viral sequence evolution outpaces CTLs to allow mutational escape during
established infection that is likely a major mechanism of viral persistence leading to CTL exhaustion and
eventual failure. Although treatment with antiretroviral therapy (ART) stops most ongoing viral replication and
could potentially allow immune regeneration that could control infection after treatment interruption, CTL
responses to decay to resting memory levels, and treatment interruption usually leads to a rapid rise in viremia
similar to acute infection.
We hypothesize that continuously driving persistence of effector CTLs against HIV-1 could interrupt this
pathogenic cycle. Rather than allowing CTLs to lag behind HIV-1, we propose a strategy to maintain levels of
HIV-1-specific effector CTLs independently of HIV-1 replication. This could prevent (in the case of an
uninfected person) or break (in the case of an infected person on ART) the pathogenic cycle leading to CTL
dysfunction. To achieve this goal, we will take advantage of the in vivo chronic antigenic stimulus of human
cytomegalovirus (CMV) to drive CTLs that recognize both CMV and HIV-1. Specifically, we aim:
1. To engineer lentiviral vectors that generate CAR T cells targeting CMV and HIV-1 simultaneously;
2. To confirm the function of these vectors in vitro as a prerequisite for future animal studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core B -Developmental Core
-
批准号:10609764
-
项目类别:
-
资助金额:$76.92万
-
财政年份:2022
-
负责人:OTTO O YANG
-
依托单位:
Core B -Developmental Core
-
批准号:10458371
-
项目类别:
-
资助金额:$142.48万
-
财政年份:2022
-
负责人:OTTO O YANG
-
依托单位:
Core B -Developmental Core
-
批准号:10874088
-
项目类别:
-
资助金额:$16.65万
-
财政年份:2022
-
负责人:OTTO O YANG
-
依托单位:
Viral Immunology Core
-
批准号:10468649
-
项目类别:
-
资助金额:$35.02万
-
财政年份:2020
-
负责人:OTTO O YANG
-
依托单位:
Viral Immunology Core
-
批准号:10614636
-
项目类别:
-
资助金额:$34.02万
-
财政年份:2020
-
负责人:OTTO O YANG
-
依托单位:
Viral Immunology Core
-
批准号:10160816
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2020
-
负责人:OTTO O YANG
-
依托单位:
Effects of Vaccine on Formation and Clearance of the HIV Latent Reservoir
-
批准号:10057935
-
项目类别:
-
资助金额:$33.84万
-
财政年份:2017
-
负责人:OTTO O YANG
-
依托单位:
Effects of Vaccine on Formation and Clearance of the HIV Latent Reservoir
-
批准号:10226142
-
项目类别:
-
资助金额:$33.68万
-
财政年份:2017
-
负责人:OTTO O YANG
-
依托单位:
CD4 T Cell Differentiation and Susceptibility to HIV-Specific CTL Killing
-
批准号:9065092
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2016
-
负责人:OTTO O YANG
-
依托单位:
Functional Assessment of CTL Anergy in HIV Infection
-
批准号:8795665
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2014
-
负责人:OTTO O YANG
-
依托单位:
Dissection of HIV-1 CTL Escape Pathways
-
批准号:9333120
-
项目类别:
-
资助金额:$41.68万
-
财政年份:2014
-
负责人:OTTO O YANG
-
依托单位:
Functional Assessment of CTL Anergy in HIV Infection
-
批准号:8738477
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2014
-
负责人:OTTO O YANG
-
依托单位:
Dissection of HIV-1 CTL Escape Pathways
-
批准号:8660215
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2014
-
负责人:OTTO O YANG
-
依托单位:
Dissection of HIV-1 CTL Escape Pathways
-
批准号:8927394
-
项目类别:
-
资助金额:$43.95万
-
财政年份:2014
-
负责人:OTTO O YANG
-
依托单位:
Bio-Nanoparticles for HIV Antigen Delivery
-
批准号:8653936
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2013
-
负责人:OTTO O YANG
-
依托单位:
Bio-Nanoparticles for HIV Antigen Delivery
-
批准号:8542347
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2013
-
负责人:OTTO O YANG
-
依托单位:
Identifying and closing gaps in TCR coverage of HIV-1 escape
-
批准号:8292302
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2011
-
负责人:OTTO O YANG
-
依托单位:
Addressing Intra-/Inter-Clade Diversity in HIV Vaccine Design by Immune Focusing
-
批准号:8058797
-
项目类别:
-
资助金额:$25.56万
-
财政年份:2010
-
负责人:OTTO O YANG
-
依托单位:
TRANSLATIONAL AIDS AND VIRAL PATHOGENESIS TRAINING (51)
-
批准号:8440316
-
项目类别:
-
资助金额:$22.46万
-
财政年份:2010
-
负责人:OTTO O YANG
-
依托单位:
TRANSLATIONAL AIDS AND VIRAL PATHOGENESIS TRAINING (51)
-
批准号:7935744
-
项目类别:
-
资助金额:$22.66万
-
财政年份:2010
-
负责人:OTTO O YANG
-
依托单位:
海外基金